Shots:

• The companies collaborated to evaluate BeiGene’s tislelizumab (anti-PD-1 immune checkpoint inhibitor) + PureTech’s LYT-200 (mAb targeting galectin-9) in patients with solid tumors associated with poor survival rates
• LYT-200 is currently being evaluated as a monothx in an adaptive P-I/II clinical trial. PureTech is expected to report the P-I results from LYT-200 monothx in Q4’21 & plans to investigate LYT-200 as a monothx & in combination with other anti-cancer treatments- including CT & other immunotherapies
• PureTech will maintain the LYT-200 program- including global R&D & commercial rights while BeiGene has agreed to supply tislelizumab for use in combination with LYT-200

  Ref: Businesswire | Image: PMLive